Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CB-103 + Letrozole |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CB-103 | CB103|CB 103 | NOTCH Inhibitor (Pan) 5 | CB-103 is a small molecule inhibitor of NOTCH signaling via inhibition of the NOTCH transcriptional activation complex, which may result in antitumor efficacy (Cancer Res 2016;76(14 Suppl):Abstract nr 338, PMID: 32601208). | |
| Letrozole | Femara | Letrozol | Aromatase Inhibitor 3 | Femara (letrozole) is an aromatase inhibitor, which inhibits estrogen synthesis, and is approved for postmenopausal women with hormone receptor positive breast cancer (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04714619 | Phase II | Anastrozole + CB-103 CB-103 + Letrozole | CB-103 Plus NSAI In Luminal Advanced Breast Cancer (CAILA) | Terminated | ESP | 0 |